LETTERS to the EDITORAIDS vaccine therapy: phase I trial
References (1)
- et al.
Expression of the HLTV-III B envelope gene by the recombinant vaccinia virus
Nature
(1986)
Cited by (38)
A brief history of the global effort to develop a preventive HIV vaccine
2013, VaccineCitation Excerpt :Interestingly, this poxvirus-prime/protein-boost protocol was not significantly different from the one used in the modestly successful Thai RV144 trial 16 years later [33]. In addition, Zagury and French collaborators also explored, in 1990, the therapeutic potential of HIV vaccines, administering to HIV-infected patients formalin inactivated autologous cells that had been previously infected ex vivo with a vaccinia vector expressing several HIV genes [34]. These pioneering efforts from Zagury, with both a preventive prime-boost approach and with a therapeutic vaccine, have almost but disappeared from the collective memory.
Vaccinia Virus Recombinants: Expression Vectors and Potential Vaccines
2012, Animal Cell BiotechnologyActive versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases
2003, Cytokine and Growth Factor ReviewsReintroduction of gene(s) into an attenuated deletion mutant of vaccinia virus strain IHD-W
1993, Microbial PathogenesisThe immune response to HIV: Implications for vaccine development
1993, Seminars in ImmunologyHuman Immunodeficiency Virus Vaccines
1993, Advances in Virus Research
Copyright © 1990 Published by Elsevier Ltd.